Placebo + SRP-1005 for huntington disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 17 Apr 2026: Trial registered, NCT07536061
  2. 12 May 2026: Trial started, NCT07536061

The trials

NCT07536061: A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease

State
Under way
Phase
Phase 1
People
32 planned
Started
12 May 2026
Primary completion
30 Nov 2027
Arms
Cohort 1: SRP-1005 Dose 1, Cohort 2: SRP-1005 Dose 2, Cohort 3: SRP-1005 Dose 3, Cohort 4: SRP-1005 Dose 4
Results
None posted
  1. 17 Apr 2026: Trial registered
  2. 12 May 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.